skip to content

Market News

Motif Bio presents drug trial data

06 October 2017 08:16

Motif Bio has presented new pre-clinical data regarding its investigational drug candidate iclaprim to the IDWeek 2017 conference in San Diego.

"The data presented today underscore the potential utility of iclaprim in a range of patient populations with suspected MRSA infections, including cystic fibrosis patients with Staphylococcus aureus lung infections," Motif Bio chief medical officer David Huang said.

At 8:16am: (LON:MTFB) Motif Bio Plc Ord 1p share price was +0.25p at 43.75p

Story provided by StockMarketWire.com

Related Company: MTFB

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?

aew-banner-180x255.jpg -

Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.